{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:49:11Z","timestamp":1793015351202,"version":"4.5.0"},"reference-count":20,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017606","name":"Optimum Patient Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,10,2]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>With the introduction of the antifibrotic drugs targeting progressive pulmonary fibroses, it becomes imperative to provide reliable contemporary estimates of the most common interstitial lung diseases. We aimed to provide contemporary estimates of the incidence and survival of idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP) and connective tissue disease-associated interstitial lung disease (CTD-ILDs), and to compare their survival to that of the general population. To do this we have used data extracted from the Optimum Patient Care Research Database (OPCRD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this matched cohort study, we extracted incident cases of HP, CTD-ILD and IPF, and age and sex matched controls for each case, for the years 2010\u20132019. We calculated annual incidence rates and analysed incidence trends over time using segmented regression modelling. We estimated survival for cases and controls using the Kaplan\u2013Meier model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We extracted data for 18\u2009914 incident cases of interstitial lung diseases between 2010 and 2019 from the OPRCD. Incidence rates varied across the different diseases, with rates of 18.12, 7.96 and 2.63 per 100\u2009000 person-years for IPF, CTD-ILD and HP, respectively. 5-year survival for IPF, CTD-ILD and HP was 40%, 54% and 66%, respectively, and this was generally \u223c50% lower than that of the general population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our population-based study emphasises the considerable burden of interstitial lung diseases, with &gt;20\u2009000 new cases diagnosed each year in the UK, many of whom will be eligible for antifibrotic drugs.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00823-2024","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T15:45:23Z","timestamp":1731599123000},"page":"00823-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Incidence and survival of interstitial lung diseases in the UK in 2010\u20132019"],"prefix":"10.1183","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3103-2665","authenticated-orcid":false,"given":"Francesca","family":"Gonnelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neva","family":"Eleangovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursie","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heath","family":"Heatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-8012","authenticated-orcid":false,"given":"Vidya","family":"Navarantam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5076-8929","authenticated-orcid":false,"given":"Tamera J.","family":"Corte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-9992","authenticated-orcid":false,"given":"David B.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0333-3308","authenticated-orcid":false,"given":"Victoria","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2522-5583","authenticated-orcid":false,"given":"Martina","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1027-7081","authenticated-orcid":false,"given":"Caitlin C.","family":"Fermoyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3063-0356","authenticated-orcid":false,"given":"Richard","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"2025030303501702000_11.2.00823-2024.1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.148031"},{"key":"2025030303501702000_11.2.00823-2024.2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1164\/rccm.201902-0467LE","article-title":"The mortality burden of idiopathic pulmonary fibrosis in the United Kingdom","volume":"200","author":"Navaratnam","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2025030303501702000_11.2.00823-2024.3","doi-asserted-by":"crossref","first-page":"1141372","DOI":"10.3389\/fmed.2023.1141372","article-title":"Global trends of interstitial lung diseases from 1990 to 2019: an age-period-cohort study based on the Global Burden of Disease study 2019, and projections until 2030","volume":"10","author":"Zeng","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2025030303501702000_11.2.00823-2024.4","doi-asserted-by":"crossref","first-page":"00058-2022","DOI":"10.1183\/23120541.00058-2022","article-title":"Interstitial lung disease incidence and mortality in the UK and the European Union: an observational study, 2001\u20132017","volume":"8","author":"Salciccioli JD","year":"2022","journal-title":"ERJ Open Res"},{"key":"2025030303501702000_11.2.00823-2024.5","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-0803"},{"key":"2025030303501702000_11.2.00823-2024.6","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-220887"},{"key":"2025030303501702000_11.2.00823-2024.7","first-page":"39","article-title":"Data-resource profile: United Kingdom optimum patient care research database","volume":"14","author":"Lynam","year":"2023","journal-title":"Pragmat Obs Res"},{"key":"2025030303501702000_11.2.00823-2024.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034428"},{"key":"2025030303501702000_11.2.00823-2024.9","unstructured":"Stuart-Buttle CD, Read JD , Sanderson HF , et al. A language of health in action: Read Codes, classifications and groupings. Proc AMIA Annu Fall Symp 1996: 75\u201379."},{"key":"2025030303501702000_11.2.00823-2024.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.24015"},{"key":"2025030303501702000_11.2.00823-2024.11","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-023-02550-0"},{"key":"2025030303501702000_11.2.00823-2024.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02080-2023"},{"key":"2025030303501702000_11.2.00823-2024.13","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0693-1"},{"key":"2025030303501702000_11.2.00823-2024.14","doi-asserted-by":"crossref","unstructured":"Gupta RS , Koteci A , Morgan A , et al. Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review. BMJ Open Respir Res 2023; 10.","DOI":"10.1136\/bmjresp-2022-001291"},{"key":"2025030303501702000_11.2.00823-2024.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02419-2016"},{"key":"2025030303501702000_11.2.00823-2024.16","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70101-8"},{"key":"2025030303501702000_11.2.00823-2024.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.08.015"},{"key":"2025030303501702000_11.2.00823-2024.18","doi-asserted-by":"crossref","first-page":"107500","DOI":"10.1016\/j.rmed.2023.107500","article-title":"Characteristics and risk factors of interstitial pneumonia with autoimmune features","volume":"221","author":"Vahidy","year":"2024","journal-title":"Respir Med"},{"key":"2025030303501702000_11.2.00823-2024.19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12931-020-1283-8","article-title":"Comorbidities and survival in patients with chronic hypersensitivity pneumonitis","volume":"21","author":"Walscher","year":"2020","journal-title":"Respir Res"},{"key":"2025030303501702000_11.2.00823-2024.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.12.030"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00823-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T11:53:10Z","timestamp":1741002790000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00823-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3,3]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1183\/23120541.00823-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00823-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]}}}